ORMP Oramed Pharmaceuticals (ORMP) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001176309
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
50
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $184.5K priced
What the filings say about ORMP
Insiders, 180 days
-$1.2M net sold
2 sellers · 50% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-01-10
Planned sales (Form 144), 90 days
$233.5K
2 notices
Oramed Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ORAMED PHARMACEUTICALS INC. insiders sold a net $1.2M of stock across 17 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 1, 2026.
- The trade is 2.3% of the 861,076 shares held after it.
- 1 other insider sold within 30 days.
- 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Gabay Avraham sold about $90.2K of ORMP under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 50 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 1, 2026.
- The trade is 2.3% of the 1,328,130 shares held after it.
- 1 other insider sold within 30 days.
- 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COO & CBO Hexter Joshua sold about $135.3K of ORMP under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 50 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 10.9% of the 671,785 shares held after it.
- 1 other insider sold within 30 days.
- 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Gabay Avraham sold about $330.7K of ORMP on Jul 1, 2026, the largest insider sale at the company since 2021; 1 other insider sold within 30 days and 50 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 13.4% of the 1,023,384 shares held after it.
- 1 other insider sold within 30 days.
- 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COO & CBO Hexter Joshua sold about $611.4K of ORMP on Jul 1, 2026, the largest insider sale at the company since 2021; 1 other insider sold within 30 days and 50 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Apr 3, 2023.
- The trade is 14.2% of the 26,809 shares held after it.
- 2 other insiders bought within 30 days.
- 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mayer Arie bought about $8.4K of ORMP on Apr 4, 2023; 2 other insiders bought within 30 days and 50 funds added in the latest 13F quarter.17 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.2M over 180 days
-$225.5K over 90 days
below 63% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
50 funds bought in last quarter
below 53% of Pharma & Biotech
Revenue
+49.3% year over year
more than 76% of Pharma & Biotech
Margin
3202.5% net margin
the highest in Pharma & Biotech
Buybacks
$4.7M repurchased, FY to 2025-12-31
below 81% of Pharma & Biotech
Short interest
4.8% of the float short (float per yahoo 2026-10-26) · 7.3 days to cover · settled 2026-09-30
below 57% of Pharma & Biotech
What changed in the last 30 days
Oct 2COO & CBO Hexter Joshua sold $135.3K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2Chief Financial Officer Gabay Avraham sold $90.2K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Officer Joshua Hexter filed to sell $140.1K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1Officer Avi Gabay filed to sell $93.4K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch ORMP
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+93.5%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ORMP: institutional holders (13F)
13F holdings, latest reported quarter
5,721,080 sh
$27.5M
2,512,175 sh
$12.1M
1,998,802 sh
$9.6M
1,608,111 sh
$7.7M
1,290,294 sh
$6.2M
Congress trades in ORMP
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-01-10 · disclosed 46 days later
$15,001 - $50,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ORMP planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Avi Gabay
Filed 2026-10-01
$93.4K
Joshua Hexter
Filed 2026-10-01
$140.1K
Gabay Avraham
Filed 2026-07-01
$449.1K
Hexter Joshua
Filed 2026-07-01
$659.0K
ORMP mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Nationwide Bailard Small Cap Value Fund
$132.2K position · as of 2026-07-31
0.1%
iShares Micro-Cap ETF
$553.0K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$36.9K position · as of 2026-06-30
0.0%
Fidelity Small Cap Value Index Fund
$234.5K position · as of 2026-06-30
0.0%
iShares Russell 2000 Value ETF
$1.5M position · as of 2026-06-30
0.0%
LVIP State Street Small-Cap Index Fund
$123.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Nadav Kidron
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.8M
$4.8M
$2.0M
+18%
n/a
2024
$2.1M
$2.1M
$1.3M
+5%
n/a
2023
$1.7M
$265.8K
$918.9K
-81%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.2M sold by insiders over 180 days, 50 funds added last quarter, $233.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ORMP financials
Revenue growth
+49.3%
XBRL, annual
Net margin
3202.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.0M
four quarters, 2025-01-01 to 2025-12-31
Revenue, TTM ORMP
| FY Dec 2025 | $2.0M |
| FY Dec 2024 | $1.3M |
| FY Dec 2023 | $1.3M |
| FY Dec 2022 | $2.7M |
| FY Aug 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $2.0M |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
+5,545%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ORMP
| FY Dec 2025 | +3.8% |
| FY Dec 2024 | -1.2% |
| FY Dec 2023 | +0.4% |
| FY Dec 2022 | n/a |
| FY Aug 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | -382.1% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$5.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ORMP
| FY Dec 2025 | -$9.2M |
| FY Dec 2024 | -$8.4M |
| FY Dec 2023 | -$10.5M |
| FY Dec 2022 | -$28.4M |
| FY Aug 2021 | n/a |
| Jun 2026 | -$202.0K |
| Mar 2026 | -$2.9M |
| Dec 2025 | -$468.0K |
| Sep 2025 | -$1.6M |
| Jun 2025 | -$3.5M |
| Mar 2025 | -$3.5M |
| Dec 2024 | -$1.9M |
| Sep 2024 | -$7.1M |
At each fiscal year end
Single quarter
Debt to equity
0.34x
long-term 2023-09-30 (33 months older than the period end) plus current 2024-03-31 (27 months older than the period end); equity 2026-06-30
Debt to equity ORMP
| FY Dec 2025 | 0.53x |
| FY Dec 2024 | 0.73x |
| FY Dec 2023 | 0.77x |
| FY Dec 2022 | 0.02x |
| FY Aug 2021 | 0.13x |
| Jun 2026 | 0.34x |
| Mar 2026 | 0.45x |
| Dec 2025 | 0.53x |
| Sep 2025 | 0.52x |
| Jun 2025 | 0.69x |
| Mar 2025 | 0.76x |
| Dec 2024 | 0.73x |
| Sep 2024 | 0.68x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.05x
TTM operating cash flow over long-term 2023-09-30 (33 months older than the period end) plus current 2024-03-31 (27 months older than the period end)
Cash flow to debt ORMP
| FY Dec 2025 | -0.09x |
| FY Dec 2024 | -0.08x |
| FY Dec 2023 | -0.08x |
| FY Dec 2022 | -10.23x |
| FY Aug 2021 | n/a |
| Jun 2026 | -0.05x |
| Mar 2026 | -0.08x |
| Dec 2025 | -0.09x |
| Sep 2025 | -0.10x |
| Jun 2025 | -0.15x |
| Mar 2025 | -0.10x |
| Dec 2024 | -0.08x |
| Sep 2024 | -0.07x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+47.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ORMP
| FY Dec 2025 | +0.0% |
| FY Dec 2024 | -0.0% |
| FY Dec 2023 | +0.0% |
| FY Dec 2022 | n/a |
| FY Aug 2021 | n/a |
| Jun 2026 | +47.0% |
| Mar 2026 | +24.3% |
| Dec 2025 | +0.0% |
| Sep 2025 | +35.0% |
| Jun 2025 | -3.1% |
| Mar 2025 | -6.0% |
| Dec 2024 | -0.0% |
| Sep 2024 | -0.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+41.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ORMP
| FY Dec 2025 | +0.0% |
| FY Dec 2024 | -0.0% |
| FY Dec 2023 | +0.0% |
| FY Dec 2022 | n/a |
| FY Aug 2021 | n/a |
| Jun 2026 | +41.7% |
| Mar 2026 | +22.1% |
| Dec 2025 | +0.0% |
| Sep 2025 | +32.6% |
| Jun 2025 | -3.0% |
| Mar 2025 | -5.2% |
| Dec 2024 | -0.0% |
| Sep 2024 | -0.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
-3.5%
operating income after a 20.6% effective tax rate, over long-term 2023-09-30 (33 months older than the period end) plus current 2024-03-31 (27 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital ORMP
| FY Dec 2025 | -5.6% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Aug 2021 | n/a |
| Jun 2026 | -3.5% |
| Mar 2026 | -4.2% |
| Dec 2025 | -5.6% |
| Sep 2025 | -4.4% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-5.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ORMP
| FY Dec 2025 | -8.4% |
| FY Dec 2024 | -8.1% |
| FY Dec 2023 | -9.8% |
| FY Dec 2022 | -24.9% |
| FY Aug 2021 | n/a |
| Jun 2026 | -5.6% |
| Mar 2026 | -7.1% |
| Dec 2025 | -8.4% |
| Sep 2025 | -7.0% |
| Jun 2025 | -8.1% |
| Mar 2025 | -9.2% |
| Dec 2024 | -8.1% |
| Sep 2024 | -8.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
1.00x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ORMP
| FY Dec 2025 | 1.91x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 16.50x |
| FY Dec 2022 | n/a |
| FY Aug 2021 | n/a |
| Jun 2026 | 1.17x |
| Mar 2026 | 1.31x |
| Dec 2025 | 1.91x |
| Sep 2025 | 2.67x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 22.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$263.1M
market value at close 2026-10-23 on 2026-08-10 shares, plus long-term 2023-09-30 (33 months older than the period end) plus current 2024-03-31 (27 months older than the period end), minus cash 2026-06-30
Enterprise value ORMP
| FY Dec 2025 | $174.1M |
| FY Dec 2024 | $149.7M |
| FY Dec 2023 | $209.7M |
| FY Dec 2022 | $432.8M |
| FY Aug 2021 | $577.9M |
| Jun 2026 | $288.2M |
| Mar 2026 | $230.9M |
| Dec 2025 | $174.1M |
| Sep 2025 | $162.7M |
| Jun 2025 | $182.7M |
| Mar 2025 | $139.6M |
| Dec 2024 | $149.7M |
| Sep 2024 | $187.5M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.0%
TTM free cash flow over market value at close 2026-10-23
FCF yield ORMP
| FY Dec 2025 | -8.1% |
| FY Dec 2024 | -8.6% |
| FY Dec 2023 | -11.3% |
| FY Dec 2022 | -6.0% |
| FY Aug 2021 | n/a |
| Jun 2026 | -2.6% |
| Mar 2026 | -6.2% |
| Dec 2025 | -8.1% |
| Sep 2025 | -9.8% |
| Jun 2025 | -17.5% |
| Mar 2025 | -12.0% |
| Dec 2024 | -8.6% |
| Sep 2024 | -8.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing ORMP
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Aug 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.00x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.0M | n/a | $1.3M | $2.7M |
| Gross profit | $13.0K | n/a | n/a | n/a |
| Operating income | -$15.1M | -$12.8M | -$15.8M | -$40.6M |
| Net income | $75.3K | -$15.9K | $5.1K | -$36.6M |
| EPS (diluted) | n/a | -0.48 | 0.14 | -0.94 |
| Operating cash flow | -$9.1M | -$8.4M | -$10.3M | -$27.9M |
| Cash | $45.9M | $54.4M | $9.1M | $40.5M |
| Long-term debt | n/a | n/a | n/a | $25.0K |
| Buybacks | $4.7M | $2.5M | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
ORMP Stock Sonar score 6/7 axes
Find similar shapesCompareORMP ranks highest on growth (76th percentile) and profitability (68th), and lowest on insider conviction (18th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ORMP filings, in plain words
Are Oramed Pharmaceuticals insiders buying or selling ORMP?
In the 180 days to 2026-10-27, Oramed Pharmaceuticals insiders were net sellers, a net $1.2M across purchases and sales reported on Form 4, by 2 sellers.
Have members of Congress traded ORMP?
Yes, but not in the year to 2026-10-27; the latest on record is a sale by Brad Knott dated 2025-01-10.
Are there planned insider sales of ORMP?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $233.5K of stock; the latest, by Avi Gabay, was filed 2026-10-01.
Read the full summary
In the 180 days to 2026-10-27, Oramed Pharmaceuticals insiders were net sellers of ORMP, a net $1.2M across purchases and sales reported on Form 4 by 2 sellers. 50% of the 4 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Members of Congress have disclosed trades in ORMP, none in the last year; the latest on record is a sale by Brad Knott dated 2025-01-10. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $233.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
